Precise, personalized therapy
Identify drug-gene interactions to maximize medicine
Pharmacogenomics (PGx) is a rapidly evolving field with the potential to affect every patient, everywhere. Studies suggest most individuals possess at least one actionable genetic variant that predisposes drug response. Establishing patients' genetic profiles allows physicians to select patient-specific medications that optimize therapeutic efficacy while avoiding adverse drug reactions.
Therapeutic areas impacted by PGx
- Infectious Disease
Paving the way for PGx implementation
The Molecular Technologies Laboratory at Mayo Clinic develops and validates PGx testing in partnership with the Center for Individualized Medicine and the Schulze Center for Novel Therapeutics. Evaluations include actionable genes with a high level of clinical evidence. Categorization of medication recommendations by drug class and reference source ensures easy interpretations for all audiences.
Increase your PGx IQ
Understanding the myriad implications that PGx testing has on patient treatment outcomes is integral to harnessing the full power of this emerging field. To educate providers about current and future PGx applications, Mayo Clinic offers a one-of-a-kind, online certificate course that guides attendees through foundational pharmacogenomics concepts and advanced decision-making. Engaging lectures, expert panels, case-based presentations, and patient role-play activities educate attendees on pharmacogenomics fundamentals, test interpretation, and tips on implementing pharmacogenomics into your practice.
The right drug for the right patient at the right dose
A comprehensive resource for ordering, interpreting, and understanding PGx testing. Indications for pharmacogenomic testing may include:
- Multiple failed therapies
- Polypharmacy cases
- Prescription risk for hypersensitivity reactions
- Family history of medication intolerance
- Symptoms suggestive of drug metabolism concern
- Severe diseases
- Elderly and pediatric patients who have difficulty communicating adverse drug reactions
Comprehensive PGx panels
- Examines 23 genes (141 alleles) used to assess approximately 80 medications.
- Identifies variations in genes known to be associated with response and/or risk of toxicity with psychotropic medications.
- Examines 10 genes (82 alleles) used to assess approximately 55 medications.
- Delivers preemptive or reactive genotyping of patients for pharmacogenetics purposes.
- Provides assessments for genes with strong drug phenotype associations.
Medication Targeted Panels
Guides therapy when analyzing multiple drug interactions that fall into the same drug class or patients with polypharmacy.
Single Gene Orders
Guides therapy when evaluating single medications or genes not included in the comprehensive panels.
Focused Pharmacogenomics Panel [A Test in Focus]
Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for patients across a variety of specialities.
Learn more about how to order these tests at your institution.